Health & Pharma Services

Graphite has wide-ranging experience of investing in pharma services, care services and medical products, where demographic and wellbeing trends underpin compelling growth dynamics. We have twice won the ‘Health Investor of the Year’ award, highlighting the financial and social impact we have made in this space.

The pharma services market benefits from favourable structural dynamics, strong innovation and constantly rising demand. We have recently backed two rapidly expanding businesses serving the global life sciences market: Random42 and Hanson Wade. Both work with pharma and biotech companies across different continents and sizes, basing their service excellence on deep scientific expertise. We have sold Random42 to a US-based MedComms business, while Hanson Wade remains in our portfolio.

In 2023, we acquired a specialist, medical products business with strong intellectual property, IPL, having had previous experience of the space through our investment in Summit Medical. Our investment focus in this area is on innovative, niche leaders who can improve quality of life.

Our healthcare providers put service excellence and quality of outcomes at the heart of their offering. Our investment is always aimed at underpinning high-quality care delivered through efficient and innovative models which can quickly gain market share, securing long-term success.